Tumor‐derived insulin‐like growth factor‐binding protein‐1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors

BACKGROUND: Antiangiogenic tyrosine kinase inhibitors (TKIs) provide one of the few therapeutic options for effective treatment of hepatocellular carcinoma (HCC). However, patients with HCC often develop resistance toward antiangiogenic TKIs, and the underlying mechanisms are not understood. The aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Hiroyuki, Iwamoto, Hideki, Seki, Takahiro, Nakamura, Toru, Masuda, Atsutaka, Sakaue, Takahiko, Tanaka, Toshimitsu, Imamura, Yasuko, Niizeki, Takashi, Nakano, Masahito, Shimose, Shigeo, Shirono, Tomotake, Noda, Yu, Kamachi, Naoki, Sakai, Miwa, Morita, Kazutoyo, Nakayama, Masamichi, Yoshizumi, Tomoharu, Kuromatsu, Ryoko, Yano, Hirohisa, Cao, Yihai, Koga, Hironori, Torimura, Takuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091105/
https://www.ncbi.nlm.nih.gov/pubmed/36825684
http://dx.doi.org/10.1002/cac2.12411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091105/
https://www.ncbi.nlm.nih.gov/pubmed/36825684
http://dx.doi.org/10.1002/cac2.12411

Ejemplares similares